Press releases
Increase of number of shares and votes in Vicore Pharma
Gothenburg, February 26, 2021– Vicore Pharma Holding AB (publ)’s (“Vicore Pharma”, or the “Company”) registered share capital and number of outstanding shares and votes have… Read more
Year-end report 2020
Gothenburg, February 26, 2021 - Vicore Pharma Holding AB (publ) publishes the year-end report for 2020. Read more
Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)
The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, with registered office in Gothenburg, are summoned to the extraordinary general meeting Friday 5… Read more
Vicore Pharma has completed a directed share issue of SEK 336 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN,… Read more
Vicore Pharma intends to carry out a directed share issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN,… Read more
Positive data from Phase II study ATTRACT in patients with COVID-19 published online
Gothenburg, February 1, 2021 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today published data… Read more
Positive results show that C21 can become an important complement to COVID-19 vaccines
Gothenburg, December 21, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today reports an… Read more
Vicore Pharma announces Last Patient Last Visit in the mechanistic phase II study with C21 in systemic sclerosis
Gothenburg, December 15, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for serious lung disorders, today announces that… Read more
Vicore Pharma reports positive top line data from the ATTRACT clinical study in patients with COVID-19
Oral C21 treatment demonstrates significant clinical improvement on top of corticosteroids Gothenburg, December 08, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated… Read more
Vicore Pharma recruits the first patient in the phase II Proof-of-Concept study in idiopathic pulmonary fibrosis
Gothenburg, November 16, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that… Read more
Increase of number of shares and votes in Vicore Pharma
Gothenburg, February 26, 2021– Vicore Pharma Holding AB (publ)’s (“Vicore Pharma”, or the “Company”) registered share capital and number of outstanding shares and votes have… Read more
Year-end report 2020
Gothenburg, February 26, 2021 - Vicore Pharma Holding AB (publ) publishes the year-end report for 2020. Read more
Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)
The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, with registered office in Gothenburg, are summoned to the extraordinary general meeting Friday 5… Read more
Vicore Pharma has completed a directed share issue of SEK 336 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN,… Read more
Vicore Pharma intends to carry out a directed share issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN,… Read more
Positive results show that C21 can become an important complement to COVID-19 vaccines
Gothenburg, December 21, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today reports an… Read more
Vicore Pharma reports positive top line data from the ATTRACT clinical study in patients with COVID-19
Oral C21 treatment demonstrates significant clinical improvement on top of corticosteroids Gothenburg, December 08, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated… Read more
Interim report July-September 2020
Gothenburg, November 6, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the third quarter 2020. Read more
Vicore announces changes in management team
Gothenburg, November 3, 2020 - Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces changes… Read more
Vicore strengthens its pipeline with the acquisition of novel AT2R agonists and decides on an issue in kind of 142,054 shares
Gothenburg, November 2, 2020 – Vicore Pharma Holding AB (publ) (“Vicore”), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces… Read more